Publication: Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<inf>gen</inf> or combined TdaP<inf>gen</inf> vaccines
Issued Date
2021-07-01
Resource Type
ISSN
25895370
Other identifier(s)
2-s2.0-85108565915
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
eClinicalMedicine. Vol.37, (2021)
Suggested Citation
Punnee Pitisuttithum, Jittima Dhitavat, Chukiat Sirivichayakul, Arom Pitisuthitham, Yupa Sabmee, Pailinrut Chinwangso, Chawanee Kerdsomboon, Librada Fortuna, Jane Spiegel, Mukesh Chauhan, Indrajeet Kumar Poredi, Anita H.J. van den Biggelaar, Wassana Wijagkanalan, Simonetta Viviani, Souad Mansouri, Hong Thai Pham Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<inf>gen</inf> or combined TdaP<inf>gen</inf> vaccines. eClinicalMedicine. Vol.37, (2021). doi:10.1016/j.eclinm.2021.100976 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78078
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<inf>gen</inf> or combined TdaP<inf>gen</inf> vaccines
Author(s)
Other Contributor(s)
Abstract
Background: Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine. Methods: Participants of a phase 2/3 randomised-controlled clinical trial with a monovalent pertussis vaccine containing genetically inactivated pertussis toxin (aPgen) or its tetanus and diphtheria toxoids combination (TdaPgen), or a chemically detoxified comparator vaccine (Tdapchem), (originally conducted between July and August 2015) were invited to participate in observational studies of persisting antibody responses 2 and 3 years after vaccination. Serum IgG against pertussis toxin (PT-IgG) and filamentous hemagglutinin (FHA-IgG) were assessed by ELISA, and PT-neutralising antibodies (PT-Nab) by Chinese Hamster Ovary cell assay. Findings: Waning of antibodies stabilised in aPgen and TdaPgen vaccinees 2 and 3 years after vaccination. Three years post-vaccination PT-neutralising antibodies remained 4·6-fold (95% Confidence Interval (CI) 2·6–8·1) and 3·7-fold (95% CI 2·2–6·1) higher, PT-IgG antibodies 3·0-fold (95% CI 2·2–4·1) and 2·5-fold (95% CI 1·9–3·3) higher, and FHA-IgG antibodies 1·8-fold (95% CI 1·3–2·5) and 1·6-fold (95% CI 1·2–2·1) higher than baseline in aPgen and TdaPgen recipients, respectively. In the Tdapchem group, PT-neutralising and PT-IgG and FHA-IgG antibodies were back at baseline levels 2 years post-vaccination. Three years post-vaccination seroconversion rates for PT-neutralising antibodies were 65·0% (95% CI 44·1–85·9) and 55·0% (95% CI 33·2–76·8) in aPgen and TdaPgen recipients, respectively. Interpretation: Considering the persistence of elevated antibody responses 3 years post-booster vaccination, genetically detoxified monovalent aPgen and TdaPgen vaccines can be expected to induce longer-lasting protection than chemically inactivated Tdap vaccines. Funding: BioNet-Asia